US Patent

US11911388 — Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

Method of Use · Assigned to Boehringer Ingelheim International GmbH · Expires 2030-04-10 · 4y remaining

Vulnerability score 64/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating diabetes in patients who have not achieved sufficient blood sugar control despite taking another diabetes medication.

USPTO Abstract

The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3854 — Tradjenta
U-3854 — Tradjenta
U-3854 — Tradjenta
U-3854 — Tradjenta
U-3854 — Tradjenta
U-3854 — Tradjenta

Patent Metadata

Patent number
US11911388
Jurisdiction
US
Classification
Method of Use
Expires
2030-04-10
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.